|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
|
CA2371427A1
(en)
|
1999-04-28 |
2000-11-09 |
Yamanouchi Pharmaceutical Co., Ltd. |
Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof
|
|
WO2001075110A2
(en)
|
2000-03-30 |
2001-10-11 |
Dyax Corp. |
Mucin-1 specific binding members and methods of use thereof
|
|
DE10303664A1
(de)
|
2003-01-23 |
2004-08-12 |
Nemod Immuntherapie Ag |
Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
|
|
US7273608B2
(en)
|
2004-03-11 |
2007-09-25 |
City Of Hope |
Humanized anti-CEA T84.66 antibody and uses thereof
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
WO2007019232A2
(en)
*
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
|
WO2007142667A2
(en)
*
|
2005-10-13 |
2007-12-13 |
Human Genome Sciences, Inc. |
Treatment of patients with autoantibody positive disease
|
|
AU2007304590A1
(en)
|
2006-10-04 |
2008-04-10 |
Cancer Research Technology Limited |
Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
|
|
CN102264765B
(zh)
|
2008-10-28 |
2016-01-20 |
盐野义制药株式会社 |
抗muc1抗体
|
|
EP2196476A1
(en)
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
|
WO2011005322A2
(en)
|
2009-07-08 |
2011-01-13 |
Lantheus Medical Imaging, Inc. |
N-alkoxyamide conjugates as imaging agents
|
|
EP2281844A1
(en)
|
2009-07-31 |
2011-02-09 |
Glycotope GmbH |
MUC 1 antibodies
|
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
CN102712921B
(zh)
|
2009-09-24 |
2017-03-01 |
株式会社遗传科技 |
特异用于胞外基质蛋白的氨基酸序列rgd的人源化抗体及其用途
|
|
EP2347769A1
(en)
|
2010-01-20 |
2011-07-27 |
Glycotope GmbH |
Cancer stem cell markers and uses thereof
|
|
WO2011135869A1
(ja)
|
2010-04-28 |
2011-11-03 |
塩野義製薬株式会社 |
新規なｍｕｃ１抗体
|
|
CN101928347B
(zh)
|
2010-05-05 |
2013-03-27 |
上海海抗中医药科技发展有限公司 |
抗癌胚抗原抗体及其应用
|
|
WO2012015912A1
(en)
|
2010-07-30 |
2012-02-02 |
Medimmune, Llc |
Method for purifying active polypeptides or immunocojugates
|
|
PE20141017A1
(es)
|
2011-03-02 |
2014-08-25 |
Roche Glycart Ag |
Anticuerpos del cea
|
|
JP6164556B2
(ja)
|
2011-12-01 |
2017-07-19 |
国立大学法人 千葉大学 |
非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤
|
|
DK3199552T3
(da)
|
2012-11-20 |
2020-03-30 |
Sanofi Sa |
Anti-ceacam5-antistoffer og anvendelser heraf
|
|
ES2673583T3
(es)
|
2013-02-28 |
2018-06-22 |
National Cancer Center |
Anticuerpo contra fibrina insoluble
|
|
TWI679019B
(zh)
|
2013-04-29 |
2019-12-11 |
法商賽諾菲公司 |
抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
|
|
NL1040254C2
(en)
*
|
2013-05-17 |
2014-11-24 |
Ablynx Nv |
Stable formulations of immunoglobulin single variable domains and uses thereof.
|
|
AU2014332442B2
(en)
|
2013-08-26 |
2019-12-19 |
Biontech Research And Development, Inc. |
Nucleic acids encoding human antibodies to Sialyl-Lewis
|
|
TWI541022B
(zh)
|
2013-12-18 |
2016-07-11 |
應克隆公司 |
針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
|
|
JP2017512814A
(ja)
*
|
2014-04-07 |
2017-05-25 |
シアトル ジェネティックス， インコーポレイテッド |
抗ｃｄ１９抗体および抗体−薬物結合体のための安定な製剤
|
|
US10239950B2
(en)
|
2014-04-28 |
2019-03-26 |
Medicinal Chemistry Pharmaceuticals, Co., Ltd. |
Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof
|
|
TWI806150B
(zh)
*
|
2014-11-07 |
2023-06-21 |
瑞士商諾華公司 |
穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
|
|
CN116199790A
(zh)
|
2015-02-10 |
2023-06-02 |
米纳瓦生物技术公司 |
人源化抗MUCl*抗体
|
|
SG10202012778YA
(en)
*
|
2015-12-18 |
2021-01-28 |
Astellas Pharma Inc |
Pharmaceutical composition comprising anti-human tslp receptor antibody
|
|
JOP20170017B1
(ar)
*
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
|
CN108699108B
(zh)
|
2016-03-01 |
2022-04-08 |
国立大学法人千叶大学 |
放射性标记药物
|
|
MX2018011675A
(es)
*
|
2016-03-25 |
2019-01-10 |
Astellas Pharma Inc |
Composicion farmaceutica que comprende un fragmento fab' pegilado de anticuerpo anti-ngf humano.
|
|
EP3479819B1
(en)
*
|
2016-06-30 |
2024-01-24 |
Celltrion Inc. |
Stable liquid pharmaceutical preparation
|
|
TWI780082B
(zh)
|
2016-11-18 |
2022-10-11 |
日商安斯泰來製藥股份有限公司 |
新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
|
|
US10758632B2
(en)
|
2017-02-06 |
2020-09-01 |
City Of Hope |
NIR-conjugated tumor-specific antibodies and uses thereof
|
|
TWI795415B
(zh)
*
|
2017-07-07 |
2023-03-11 |
日商安斯泰來製藥股份有限公司 |
新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
|
|
US11167050B2
(en)
|
2017-09-26 |
2021-11-09 |
National University Corporation Chiba University |
Metal complex forming compound, metal complex compound formed thereof, radioactive drug containing the metal complex compound, and method of using and preparing the metal complex compound
|
|
BR112020023420A8
(pt)
|
2018-05-17 |
2022-07-05 |
Astellas Pharma Inc |
Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
|
|
SG11202103670XA
(en)
|
2018-10-10 |
2021-05-28 |
Astellas Pharma Inc |
Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
|
|
MX2021008230A
(es)
|
2019-01-07 |
2021-08-11 |
Astellas Pharma Inc |
Conjugado que comprende ligando y fragmento fab de anticuerpo ceacam5.
|